Raphael Rosenhek

Raphael Rosenhek

Auto-generated profile, based on publicly available information

Raphael Rosenhek

Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2010 in Circulation
Verified
Journal Article
Closed access
PDF file
RRRaphael Rosenhek
Raphael Rosenhek
Robert ZilberszacRobert Zilberszac
Robert Zilberszac
MSMichael Schemper
Michael Schemper
Martin CzernyMartin Czerny
Martin Czerny
GMGerald Mundigler
Gerald Mundigler
GMGerald Maurer
Gerald Maurer
Background— We sought to assess the outcome of asymptomatic patients with very severe aortic stenosis. Methods and Results— We prospectively followed 116 consecutive asymptomatic patients (57 women; age, 67±16 years) with very severe isolated aortic stenosis defined by a peak aortic jet velocity (AV-Vel) ≥5.0 m/s (average AV-Vel, 5.37±0.35 m/s; valve area, 0.63±0.12 cm 2 ). During a median follow-up of 41 months (interquartile range, 26 to 63 months), 96 events occurred (indication for aortic valve replacement, 90; cardiac deaths, 6). Event-free survival was 64%, 36%, 25%, 12%, and 3% at 1, 2, 3, 4, and 6 years, respectively. AV-Vel but not aortic valve area was shown to independently affect event-free survival. Patients with an AV-Vel ≥5.5 m/s had an event-free survival of 44%, 25%, 11%, and 4% at 1, 2, 3, and 4 years, respectively, compared with 76%, 43%, 33%, and 17% for patients with an AV-Vel between 5.0 and 5.5 m/s ( P II) than those with an AV-Vel between 5.0 and 5.5 m/s (27%; P =0.03). Conclusions— Despite being asymptomatic, patients with very severe aortic stenosis have a poor prognosis with a high event rate and a risk of rapid functional deterioration. Early elective valve replacement surgery should therefore be considered in these patients.

9 May 2006 in Circulation
Verified
Journal Article
Closed access
PDF file
RRRaphael Rosenhek
Raphael Rosenhek
FRFlorian Rader
Florian Rader
UKUrsula Klaar
Ursula Klaar
HGHarald Gabriel
Harald Gabriel
MKMarcel Krejc
Marcel Krejc
HBHelmut Baumgartner
Helmut Baumgartner
Background— The management of asymptomatic severe mitral regurgitation remains controversial. The aim of this study was to evaluate the outcome of a watchful waiting strategy in which patients are referred to surgery when symptoms occur or when asymptomatic patients develop left ventricular (LV) enlargement, LV dysfunction, pulmonary hypertension, or recurrent atrial fibrillation. Methods and Results— A total of 132 consecutive asymptomatic patients (age 55±15 years, 49 female) with severe degenerative mitral regurgitation (flail leaflet or valve prolapse) were prospectively followed up for 62±26 months. Patients underwent serial clinical and echocardiographic examinations and were referred for surgery when the criteria mentioned above were fulfilled. Overall survival was not statistically different from expected survival either in the total group or in the subgroup of patients with flail leaflet. Eight deaths were observed. Thirty-eight patients developed criteria for surgery (symptoms, 24; LV criteria, 9; pulmonary hypertension or atrial fibrillation, 5). Survival free of any indication for surgery was 92±2% at 2 years, 78±4% at 4 years, 65±5% at 6 years, and 55±6% at 8 years. Patients with flail leaflet tended to develop criteria for surgery slightly but not significantly earlier. There was no operative mortality. Postoperative outcome was good with regard to survival, symptomatic status, and postoperative LV function. Conclusions— Asymptomatic patients with severe degenerative mitral regurgitation can be safely followed up until either symptoms occur or currently recommended cutoff values for LV size, LV function, or pulmonary hypertension are reached. This management strategy is associated with good perioperative and postoperative outcome but requires careful follow-up.

7 September 2004 in Circulation
Verified
Journal Article
Closed access
RRRaphael Rosenhek
Raphael Rosenhek
FRFlorian Rader
Florian Rader
NLNicole Loho
Nicole Loho
HGHarald Gabriel
Harald Gabriel
MHMaria Heger
Maria Heger
HBHelmut Baumgartner
Helmut Baumgartner
Background— Recently, statins and angiotensin-converting enzyme inhibitors (ACEIs) have been shown to slow aortic valve calcium accumulation. Although several studies also suggest that statins may reduce the hemodynamic progression of aortic stenosis (AS), no data are available for ACEIs or the combination of both. Methods and Results— A total of 211 consecutive patients (aged 70±10 years, 104 females) with native AS, defined by a peak velocity >2.5 m/s (valve area 0.84±0.23 cm 2 , mean gradient 42±19 mm Hg), with normal left ventricular function and no other significant valvular lesion who were examined between 2000 and 2002 and who had 2 echocardiograms separated by at least 6 months were included. Of these, 102 patients were treated with ACEIs, 50 patients received statins, and 32 patients received both. Hemodynamic progression of AS was assessed and related to medical treatment. Annualized increase in peak aortic jet velocity for the entire study group was 0.32±0.44 m · s −1 · y −1 . Progression was significantly lower in patients treated with statins (0.10±0.41 m · s −1 · y −1 ) than in those who were not (0.39±0.42 m · s −1 · y −1 ; P <0.0001). This effect was observed both in mild-to-moderate and severe AS. ACEI use, however, did not significantly affect hemodynamic progression ( P =0.29). Furthermore, ACEIs had no additional effect on AS progression when given in combination with statins (0.11±0.42 versus 0.08±0.43 m · s −1 · y −1 for combination versus statin only; P =0.81). Cholesterol levels did not correlate with hemodynamic progression either in the group receiving statins or in the group that did not. Conclusions— ACEIs do not appear to slow AS progression. However, statins significantly reduce the hemodynamic progression of both mild-to-moderate and severe AS, an effect that may not be related to cholesterol lowering.

15 March 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RRRaphael Rosenhek
Raphael Rosenhek
BIBernard Iung
Bernard Iung
PTPilar Tornos
Pilar Tornos
MAManuel J. Antunes
Manuel J. Antunes
BPBernard D. Prendergast
Bernard D. Prendergast
CGChrista Gohlke-Bärwolf
Christa Gohlke-Bärwolf
Risk scores provide an important contribution to clinical decision-making, but their validity has been questioned in patients with valvular heart disease (VHD), since current scores have been mainly derived and validated in adults undergoing coronary bypass surgery. The Working Group on Valvular Heart Disease of the European Society of Cardiology reviewed the performance of currently available scores when applied to VHD, in order to guide clinical practice and future development of new scores. The most widely used risk scores (EuroSCORE, STS, and Ambler score) were reviewed, analysing variables included and their predictive ability when applied to patients with VHD. These scores provide relatively good discrimination, i.e. a gross estimation of risk category, but cannot be used to estimate the exact operative mortality in an individual patient because of unsatisfactory calibration. Current risk scores do not provide a reliable estimate of exact operative mortality in an individual patient with VHD. They should therefore be interpreted with caution and only used as part of an integrated approach, which incorporates other patient characteristics, the clinical context, and local outcome data. Future risk scores should include additional variables, such as cognitive and functional capacity and be prospectively validated in high-risk patients. Specific risk models should also be developed for newer interventions, such as transcatheter aortic valve implantation.

1 January 2017 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
Robert ZilberszacRobert Zilberszac
Robert Zilberszac
HGHarald Gabriel
Harald Gabriel
MSMichael Schemper
Michael Schemper
GLGünther Laufer
Günther Laufer
GMGerald Maurer
Gerald Maurer
RRRaphael Rosenhek
Raphael Rosenhek

1 September 2018 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
Robert ZilberszacRobert Zilberszac
Robert Zilberszac
Georg HeinzeGeorg Heinze
Georg Heinze
TBThomas Binder
Thomas Binder
GLGünther Laufer
Günther Laufer
HGHarald Gabriel
Harald Gabriel
RRRaphael Rosenhek
Raphael Rosenhek